Robust Treatment Options Remain Limited for Stimulant Use Disorder
Prescribers treating stimulant use disorders remain limited to off-label medication options at a time when stimulant use and overdose rates are on the rise. At Psych Congress 2019, UCLA Associate Clinical Professor of Psychiatry Larissa Mooney, MD, offered an overview of medication treatment choices that are considered promising but far from proven.
Other Articles in this Edition
CHADD Hosts Summit to Address Impact of ADHD on Public Health
Robust Treatment Options Remain Limited for Stimulant Use Disorder
Does Seeing ADHD as a Continuum Decrease Stigma?
Current ADHD medications provide patients, clinicians with ‘exciting’ options
PM Stimulant Eases Daily Life for Kids With ADHD
This is what it’s like to be in a relationship with someone who has ADHD
Children With ADHD 40 Years Later
I’m a CEO with ADHD, and it’s my biggest strength. Here’s why.
Why there is no such thing as a ‘normal’ brain